Literature DB >> 25039550

Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between likert and visual analog scales.

Peter S Pang1, Sean P Collins, Kori Sauser, Adin-Cristian Andrei, Alan B Storrow, Judd E Hollander, Miguel Tavares, Jindrich Spinar, Cezar Macarie, Dimitar Raev, Richard Nowak, Mihai Gheorghiade, Alexandre Mebazaa.   

Abstract

BACKGROUND: Dyspnea is the most common symptom in acute heart failure (AHF), yet how to best measure it has not been well defined. Prior studies demonstrate differences in dyspnea improvement across various measurement scales, yet these studies typically enroll patients well after the emergency department (ED) phase of management.
OBJECTIVES: The aim of this study was to determine predictors of early dyspnea improvement for three different, commonly used dyspnea scales (i.e., five-point absolute Likert scale, 10-cm visual analog scale [VAS], or seven-point relative Likert scale).
METHODS: This was a post hoc analysis of URGENT Dyspnea, an observational study of 776 patients in 17 countries enrolled within 1 hour of first physician encounter. Inclusion criteria were broad to reflect real-world clinical practice. Prior literature informed the a priori definition of clinically significant dyspnea improvement. Resampling-based multivariable models were created to determine patient characteristics significantly associated with dyspnea improvement.
RESULTS: Of the 524 AHF patients, approximately 40% of patients did not report substantial dyspnea improvement within the first 6 hours. Baseline characteristics were similar between those who did or did not improve, although there were differences in history of heart failure, coronary artery disease, and initial systolic blood pressure. For those who did improve, patient characteristics differed across all three scales, with the exception of baseline dyspnea severity for the VAS and five-point Likert scale (c-index ranged from 0.708 to 0.831 for each scale).
CONCLUSIONS: Predictors of early dyspnea improvement differ from scale to scale, with the exception of baseline dyspnea. Attempts to use one scale to capture the entirety of the dyspnea symptom may be insufficient.
© 2014 by the Society for Academic Emergency Medicine.

Entities:  

Mesh:

Year:  2014        PMID: 25039550      PMCID: PMC4105984          DOI: 10.1111/acem.12390

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  20 in total

1.  Beyond dyspnoea as an endpoint in acute heart failure trials.

Authors:  Mihai Gheorghiade; Frank Ruschitzka
Journal:  Eur Heart J       Date:  2011-03-08       Impact factor: 29.983

2.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

3.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  William T Abraham; Kirkwood F Adams; Gregg C Fonarow; Maria Rosa Costanzo; Robert L Berkowitz; Thierry H LeJemtel; Mei L Cheng; Janet Wynne
Journal:  J Am Coll Cardiol       Date:  2005-07-05       Impact factor: 24.094

4.  Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.

Authors:  Peter S Pang; Mihai Gheorghiade; Jamil Dihu; Karl Swedberg; Sadiya Khan; Aldo P Maggioni; Liliana Grinfeld; Faiez Zannad; John C Burnett; John Ouyang; James E Udelson; Marvin A Konstam
Journal:  Am Heart J       Date:  2011-06       Impact factor: 4.749

5.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Authors:  John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

6.  Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study.

Authors:  Marco Metra; John G Cleland; Beth Davison Weatherley; Howard C Dittrich; Michael M Givertz; Barry M Massie; Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Gad Cotter
Journal:  Eur J Heart Fail       Date:  2010-03-12       Impact factor: 15.534

7.  Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.

Authors:  Marco Metra; Christopher M O'Connor; Beth A Davison; John G F Cleland; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Michael M Givertz; George A Mansoor; Daniel M Bloomfield; Gang Jia; Paul DeLucca; Barry Massie; Howard Dittrich; Gad Cotter
Journal:  Eur Heart J       Date:  2011-03-08       Impact factor: 29.983

Review 8.  A review of dyspnea in acute heart failure syndromes.

Authors:  Ryenn L West; Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Robert M Califf
Journal:  Am Heart J       Date:  2010-08       Impact factor: 4.749

9.  Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF.

Authors:  Robert J Mentz; Adrian F Hernandez; Amanda Stebbins; Justin A Ezekowitz; G Michael Felker; Gretchen M Heizer; Dan Atar; John R Teerlink; Robert M Califf; Barry M Massie; Vic Hasselblad; Randall C Starling; Christopher M O'Connor; Piotr Ponikowski
Journal:  Eur J Heart Fail       Date:  2012-11-15       Impact factor: 15.534

10.  Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful?

Authors:  Douglas S Ander; Imoigele P Aisiku; Jonathan J Ratcliff; Knox H Todd; Karen Gotsch
Journal:  Congest Heart Fail       Date:  2004 Jul-Aug
View more
  8 in total

Review 1.  Patient selection in heart failure with preserved ejection fraction clinical trials.

Authors:  Jacob P Kelly; Robert J Mentz; Alexandre Mebazaa; Adriaan A Voors; Javed Butler; Lothar Roessig; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor; Carolyn S P Lam
Journal:  J Am Coll Cardiol       Date:  2015-04-28       Impact factor: 24.094

2.  Identifying unique profiles of perceived dyspnea burden in heart failure.

Authors:  Kenneth M Faulkner; Corrine Y Jurgens; Quin E Denfeld; Karen S Lyons; Jessica Harman Thompson; Christopher S Lee
Journal:  Heart Lung       Date:  2020-05-18       Impact factor: 2.210

Review 3.  Expanded algorithm for managing patients with acute decompensated heart failure.

Authors:  Joyce N Njoroge; Baljash Cheema; Andrew P Ambrosy; Stephen J Greene; Sean P Collins; Muthiah Vaduganathan; Alexandre Mebazaa; Ovidiu Chioncel; Javed Butler; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

4.  The Role of Red Blood Cell Distribution Width for Predicting 1-year Mortality in Patients Admitted to the Emergency Department with Severe Dyspnoea.

Authors:  Gianni Turcato; Gianfranco Cervellin; Gian Luca Salvagno; Eleonora Zaccaria; Giuseppe Bartucci; Marco David; Antonio Bonora; Massimo Zannoni; Giorgio Ricci; Giuseppe Lippi
Journal:  J Med Biochem       Date:  2017-01-25       Impact factor: 3.402

5.  Surface respiratory electromyography and dyspnea in acute heart failure patients.

Authors:  Daniele Luiso; Jair A Villanueva; Laia C Belarte-Tornero; Aleix Fort; Zorba Blázquez-Bermejo; Sonia Ruiz; Ramon Farré; Jordi Rigau; Julio Martí-Almor; Núria Farré
Journal:  PLoS One       Date:  2020-04-29       Impact factor: 3.240

6.  Corona Virus Disease 19 (CoViD-19) impact on cardiovascular disease in a non-CoViD-19 emergency setting.

Authors:  Sebastiano Cicco; Rocco Guerra; Angela Leaci; Anna Mundo; Angelo Vacca; Maria Teresa Montagna; Vito Racanelli
Journal:  Intern Emerg Med       Date:  2021-01-05       Impact factor: 3.397

7.  Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro.

Authors:  Nathan Robbins; Mark Gilbert; Mohit Kumar; James W McNamara; Patrick Daly; Sheryl E Koch; Ginger Conway; Mohamed Effat; Jessica G Woo; Sakthivel Sadayappan; Jack Rubinstein
Journal:  J Am Heart Assoc       Date:  2018-01-13       Impact factor: 5.501

Review 8.  Approach to Adult Patients with Acute Dyspnea.

Authors:  Elizabeth DeVos; Lisa Jacobson
Journal:  Emerg Med Clin North Am       Date:  2016-02       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.